Oblato
Private Company
Funding information not available
Overview
Oblato is a clinical-stage biotech company advancing OKN-007, a free radical scavenger, for the treatment of aggressive brain cancers. The company has secured key regulatory designations from the FDA, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations, underscoring the significant unmet need in its target indications. Its development strategy includes both intravenous and oral formulations, with ongoing Phase 2 trials in recurrent GBM and plans for a trial in DIPG. As a private subsidiary of HLB Therapeutics, Oblato's progress is closely tied to the clinical success of its single lead candidate.
Technology Platform
Development of OKN-007, a nitrone derivative and free radical scavenger that modulates the tumor microenvironment by reducing reactive oxygen species, necrosis, hypoxia, inflammation, and angiogenesis.
Opportunities
Risk Factors
Competitive Landscape
Oblato competes in the challenging neuro-oncology space against companies developing a range of therapies including tumor-treating fields (Novocure), targeted therapies, immunotherapies, and novel drug delivery technologies. For DIPG, the competitive field is smaller due to the rarity of the disease, but it includes other investigational agents in early clinical development. OKN-007's unique mechanism of modulating the tumor microenvironment differentiates it from direct cytotoxic or targeted approaches.